Tag - WVE

Developments

Wave Life flunks Phase 1b/2a study in ALS and dementia

Wave Life Sciences’ (NASDAQ:WVE) drug candidate, WVE-004, did not show clinical benefit, compared with placebo, in the Phase 1b/2a FOCUS-C9 study as an investigational treatment for C9orf72-associated amyotrophic...

May 23, 2023

Markets

SVB Leerink ups Wave Life Sciences PT to $46 from $40

SVB Leerink raised its price target for Wave Life Sciences (NASDAQ:WVE) to $46 from $40 after the FDA approved Sarepta Therapeutics’ (NASDAQ:SRPT) golodirsen for the treatment of Duchenne muscular dystrophy (DMD) in...

December 13, 2019

Developments

Wave Life Sciences gets FDA fast track designation for suvodirsen

Wave Life Sciences (NASDAQ:WVE) received FDA fast track designation for suvodirsen for the treatment of Duchenne muscular dystrophy (DMD). DMD is a genetic disorder caused by the absence of dystrophin – a protein that...

September 16, 2019

Markets

Mizuho starts Wave Life Sciences at buy

Mizuho Securities initiated coverage of Wave Life Sciences (NASDAQ:WVE) with a “buy” rating and price target of $34. The stock closed at $17.50 on August 16. Analyst Salim Syed writes that Wave is an idea-rich, nucleic...

August 18, 2017

Tag - WVE

Wave Life flunks Phase 1b/2a study in ALS and dementia

SVB Leerink ups Wave Life Sciences PT to $46 from $40

Wave Life Sciences gets FDA fast track designation for suvodirsen

Mizuho starts Wave Life Sciences at buy

General

More